Volume 30 Issue 3-4, April 2023
Cover Credit: Gene therapy for patients with advanced neovascular age-related macular degeneration has reached clinical trial phases by introducing sFLT01. htsFLT01 gene construct is a novel anti-angiogenic tool with promising improvements compared to existing treatments. The critical properties of htsFLT01 molecule were maintained in desired limits post hinge deletion process when compared to sFLT01 protein. While, hinge shrinkage led to increased flexibility, stability and safety profile and decreased antigenicity of the htsFLT01 molecule. The image shows confocal microscopy of retinal vasculature in P16 mice, 2 weeks after AAV2-htsFLT01 intravitreal delivery. The presence of isolectin-positive dots in htsFLT01 treated eyes was the result of attenuation and impaired vascular formation due to anti-angiogenic effects of htsFLT01 protein.
Perspective
-
Advertisement
